文献速递基础与转化研究

选择性Bcl-2抑制在非人灵长类中促进造血嵌合与同种异体移植物耐受且不引起骨髓抑制

Selective Bcl-2 inhibition promotes hematopoietic chimerism and allograft tolerance without myelosuppression in nonhuman primates.
PubMed 文献 · Sci Transl Med · 2023-04-05

在非人灵长类模型中,选择性抑制Bcl-2可在部分清除宿主造血干细胞和有效清除外周淋巴细胞的同时保留髓系细胞与调节性T细胞,从而促进造血嵌合和肾同种异体移植物耐受;单用Bcl-2抑制不足以诱导造血嵌合,但加用Bcl-2抑制剂可在仅使用既往所需全身照射剂量一半的情况下促进造血嵌合和肾同种异体移植物耐受。

要点

  • 选择性Bcl-2抑制可在保留髓系细胞和调节性T细胞的同时部分清除造血干细胞。
  • 单用Bcl-2抑制不足以诱导造血嵌合。
  • 加用Bcl-2抑制剂可在全身照射剂量减半下促进造血嵌合和肾同种异体移植物耐受。

核心结论

  • 选择性抑制Bcl-2是在不引起骨髓抑制情况下诱导造血嵌合的有前景方法,并有可能使造血干细胞移植更适用于多种临床适应症。

研究设计与样本

  • 在临床相关的非人灵长类模型中开展的研究。

主要发现

  • 选择性抑制Bcl-2在部分清除造血干细胞和有效清除外周淋巴细胞的同时保留髓系细胞与调节性T细胞,促进造血嵌合和肾同种异体移植物耐受。
  • 单用Bcl-2抑制不足以诱导造血嵌合。
  • 加用Bcl-2抑制剂可在仅使用既往所需全身照射剂量一半的情况下促进造血嵌合和肾同种异体移植物耐受。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematopoietic stem cell transplantation (HSCT) has many potential applications beyond current standard indications, including treatment of autoimmune disease, gene therapy, and transplant tolerance induction. However, severe myelosuppression and other toxicities after myeloablative conditioning regimens have hampered wider clinical use. To achieve donor hematopoietic stem cell (HSC) engraftment, it appears essential to establish niches for the donor HSCs by depleting the host HSCs. To date, this has been achievable only by nonselective treatments such as irradiation or chemotherapeutic drugs. An approach that is capable of more selectively depleting host HSCs is needed to widen the clinical application of HSCT. Here, we show in a clinically relevant nonhuman primate model that selective inhibition of B cell lymphoma 2 (Bcl-2) promoted hematopoietic chimerism and renal allograft tolerance after partial deletion of HSCs and effective peripheral lymphocyte deletion while preserving myeloid cells and regulatory T cells. Although Bcl-2 inhibition alone was insufficient to induce hematopoietic chimerism, the addition of a Bcl-2 inhibitor resulted in promotion of hematopoietic chimerism and renal allograft tolerance despite using only half of the dose of total body irradiation previously required. Selective inhibition of Bcl-2 is therefore a promising approach to induce hematopoietic chimerism without myelosuppression and has the potential to render HSCT more feasible for a variety of clinical indications.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Sasaki H, Hirose T, Oura T, et al. Selective Bcl-2 inhibition promotes hematopoietic chimerism and allograft tolerance without myelosuppression in nonhuman primates. Sci Transl Med. 2023. PMID: 37018417. doi:10.1126/scitranslmed.add5318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。